CollPlant Biotechnologies Ltd. reported its financial results for the three months ended March 31, 2025. The company experienced a significant increase in revenues, which rose to $2.055 million compared to $98,000 in the same period the previous year. Despite the increase in revenues, the company reported a net loss of $1.452 million, a notable improvement from the $4.195 million loss reported in the first quarter of 2024. The total operating loss for the quarter was $1.648 million, down from $4.329 million the year prior. This improvement in financial performance is reflected in the non-GAAP net loss, which decreased to $1.130 million from $3.954 million in the previous year. CollPlant's management emphasized that the non-GAAP financial measures provide meaningful supplemental information regarding the company's performance, excluding non-cash expenses related to share-based compensation and changes in operating lease accounts. No specific outlook or guidance for future periods was provided in the release.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。